



(Formerly known as Intercontinental Leasing & Finance Company Limited)

CIN: L24100GJ1984PLC111413

Reg. Office : 501, Aditraj Arcade, Near Hetvi Tower, Opp. Titanium City Center, 100 Ft. ring road, Satellite, Ahmedabad -380015.

**Date: 14<sup>th</sup> August, 2021**

To,

Listing Compliances, <b>BSE Limited,</b> P. J. Towers, Fort, Mumbai - 400001. <b>Scrip Code: 539938; Scrip Id: MIL</b>	Listing Compliances, <b>CSE - India,</b> 7, Lyons Range, Dalhousie Kolkata - 700001.
--	---

**Subject: Outcome of Board Meeting and Compliances of Regulation 30 and 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015.**

Dear Sir/Ma'am,

Pursuant to provisions of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, this is to inform you that the Board of Directors of the Company at its meeting held today i.e., August 14, 2021, inter alia, considered and approved the following matters:

1. Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended on June 30, 2021 along with Limited Review Report issued by M/s. V Goswami & Co, Statutory Auditors of the Company.
2. Notice of Annual General Meeting, Board's report along with annexures thereon.
3. The Annual General Meeting of the Company will be held on Thursday, 30<sup>th</sup> September, 2021 at 12:00 P.M. through Video Conferencing (VC) / Other Audio Visual Means (OAVM).
4. The cut-off date for the purpose of the Annual General Meeting is 23<sup>rd</sup> September, 2021.
5. The Register of members and share transfer books will remain closed from 24<sup>th</sup> September, 2021 to 30<sup>th</sup> September, 2021 (both days inclusive) for the purpose of the AGM.
6. The e-voting will commence from 27<sup>th</sup> September, 2021 at 9:00 A.M. and shall conclude on 29<sup>th</sup> September, 2021 at 5:00 P.M.
7. Mr. Yash Mehta, Practicing Company Secretary has been appointed as Scrutinizer for the purpose of e-voting at Annual General Meeting.

Further, please find enclosed "Standalone and Consolidated Unaudited Financial Results along with Limited Review Report" for the quarter ended on June 30, 2021 as **Annexure 1** and same is also available on the website of the Company viz. [www.medicointercontinental.com](http://www.medicointercontinental.com)

The Board Meeting of the Company commenced at 12:30 P.M. and concluded at 02:30 P.M.

This is for your information and records.

Thanking You,

**FOR MEDICO INTERCONTINENTAL LIMITED**

(formerly known as Intercontinental Leasing and Finance Company Limited)

  
**Puneeta Sharma**  
**Company Secretary & Compliance Officer**



Godown Address : 12 & 19/1a, Madhav Estate, Near IBP Petrol Pump, Forest Section-1, Aslali, Ahmedabad-382427.

Ph. No.: 079 – 26742739, Fax No. 079 – 26742740. Email ID – mail@medicointercontinental.com Website: www.medicointercontinental.com



**V.GOSWAMI & CO.**  
**CHARTERED ACCOUNTANTS**

PEER REVIEW :- 011190

ISO 9001:2015 CERTIFIED

MSME :- GJ01D0134595

GST : 24AAHFV3075F1Z7

3, SF, Manek Apartment, Nr. Jain Derasar, Above Dena Bank, Nehrunagar Circle, Ahmedabad-380015.  
M : +91 94287 33427 | E-mail : thegoswami@gmail.com | canilesh.vgc@gmail.com | www.goswami.in

**Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015( as amended)**

**TO THE BOARD OF DIRECTORS OF MEDICO INTERCONTINENTAL LIMITED**

We have reviewed the accompanying Statements of Standalone Unaudited Financial Results of MEDICO INTERCONTINENTAL LIMITED ("the company" ), for the quarter ended June 30, 2021 ("the Statement") , being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including relevant circulars issued by the SEBI from time to time.

This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity ', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.







**V.GOSWAMI & CO.**  
**CHARTERED ACCOUNTANTS**

PEER REVIEW :- 011190  
ISO 9001:2015 CERTIFIED  
MSME :- GJ01D0134595  
GST : 24AAHFV3075F1Z7

3, SF, Manek Appartment, Nr. Jain Derasar, Above Dena Bank, Nehrunagar Circle, Ahmedabad-380015.  
M : +91 94287 33427 | E-mail : thegoswami@gmail.com | canilesh.vgc@gmail.com | www.goswami.in

Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For, V. GOSWAMI & CO,  
Chartered Accountants  
(FRN:0128769W)

Nilesh Purohit  
(Partner)

Mem No:162541

Place :-Ahmedabad

Date :- 14/08/2021

UDIN: 21162541AAAACZ6055



<b>MEDICO INTERCONTINENTAL LIMITED</b> <b>CIN: L24100GJ1984PLC111413</b> <b>Regd. Off: 1-5TH FLOOR, ADIT RAJ ARCADE, NR KARMA SHRESHTHA TOWER, 100 FT RD, SATELLITE, AHMEDABAD, GJ - 380015</b> <b>Tel No. 079-26742739 E-mail:- mail@medicointercontinental.com Website: www.medicointercontinental.com</b> <b>Statement of Standalone Unaudited Financial Results for the Quarter ended June 30, 2021 (Rs. in Lakhs)</b>				
Sr. No.	Particulars	Quarter ended		
		STANDALONE		
		3 Months ended	Preceding 3 Months ended	Corresponding 3 months ended in
		30-06-2021	31-03-2021	30-06-2020
		Unaudited	Refer note-3	Unaudited
				31-03-2021
				Audited
	<b>Revenues</b>			
1	Revenue from Operations	1122.47	784.17	1367.00
2	Other Income	1.07	0.70	11.19
3	<b>Total Revenue (A)</b>	<b>1123.54</b>	<b>784.87</b>	<b>1378.20</b>
4	<b>Expenses</b>			
(a)	Cost of materials consumed	0.00	0.00	0.00
(b)	Purchases of stock-in-trade	897.23	692.44	1322.39
(c)	Changes in inventories of finished goods and stock-in-trade	110.58	-28.47	-107.83
(d)	Employee benefits expense	18.05	17.62	20.65
(e)	Finance costs	18.22	16.33	20.34
(f)	Depreciation and amortisation expense	2.38	1.95	1.09
(g)	Other expenses	32.18	44.95	79.56
	<b>Total Expenses (B)</b>	<b>1078.64</b>	<b>744.82</b>	<b>1336.19</b>
5	<b>Profit/(Loss) before exceptional items &amp; tax (1-4)</b>	<b>44.90</b>	<b>40.06</b>	<b>42.01</b>
6	Exceptional items			
7	<b>Profit/(Loss) for the period from operations before tax</b>	<b>44.90</b>	<b>40.06</b>	<b>42.01</b>
8	Tax expense	11.43	15.40	10.36
(a)	Current Tax	11.76	15.47	10.50
(b)	Deferred Tax	-0.33	-0.07	-0.14
9	<b>Profit/(Loss) for the period from continuing operations (7-8)</b>	<b>33.47</b>	<b>24.65</b>	<b>31.65</b>
10	Profit/(loss) for the period from discontinued operations	0.00	0.00	0.00
11	Tax expense of discontinued operations	0.00	0.00	0.00
12	Profit/(loss) for the period from Discontinued operations	0.00	0.00	0.00
13	Profit/ (loss) for the period (After tax)	<b>33.47</b>	<b>24.65</b>	<b>31.65</b>
14	Other Comprehensive Income			
15	<b>Total Comprehensive Income for the period (13+14)</b>	<b>33.47</b>	<b>24.65</b>	<b>31.65</b>
	Paid-up Equity Share Capital (Face Value INR 10 each)	324.90	324.90	324.90
16	<b>Earnings Per Equity Share of Rs. 10 each (for continuing Operations)</b>			
(a)	(Basic) - INR	1.03	0.76	0.97
(b)	(Diluted) - INR	1.03	0.76	0.97
17	<b>Earnings Per Equity Share of Rs. 10 each (for discontinuing Operations)</b>			
(a)	(Basic) - INR	0.00	0.00	0.00
(b)	(Diluted) - INR	0.00	0.00	0.00
18	<b>Earnings Per Equity Share of Rs. 10 each (for continuing &amp; discontinuing Operations)</b>			
(a)	(Basic) - INR	1.03	0.76	0.97
(b)	(Diluted) - INR	1.03	0.76	0.97

- The above unaudited standalone financial results of the Company for the quarter ended June 30, 2021 have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on August 14, 2021. The above results reviewed by statutory auditors and who have expressed an unmodified opinion on these results.
- During the quarter ended 30<sup>th</sup> June, 2021, the company is operating in single segment. So segment reporting is not applicable for this quarter, but segment information shall be provides when it applicable.
- Figures for the quarter ended 31 March 2021 are the balancing figures between audited figures for the full financial year and the reviewed year to date figures up to the third quarter of the financial year.
- The Company has considered possible effects that may result from COVID-19 in preparation of these results including recoverability of assets including inventories and trade receivables. In developing the assumptions relating to future uncertainties in the economic conditions due to COVID-19, it has, at the date of approval of these results, used relevant internal and external sources of information including economic forecasts and expects that the carrying amounts of these assets are recoverable. The impact of COVID-19 may be different from that estimated as at the date of approval of these standalone financial results.
- The previous period figures have been re-grouped / reclassified, wherever considered necessary, to make them comparable.

For, Medico Intercontinental Limited

**SAMIR SHAH**  
**MANAGING DIRECTOR**  
**DIN: 03350268**

Place: Ahmedabad  
Date: 14/08/2021







**V.GOSWAMI & CO.**  
**CHARTERED ACCOUNTANTS**

PEER REVIEW :- 011190  
ISO 9001:2015 CERTIFIED  
MSME :- GJ01D0134595  
GST : 24AAHFV3075F1Z7

3, SF, Manek Appartment, Nr. Jain Derasar, Above Dena Bank, Nehrunagar Circle, Ahmedabad-380015.  
M : +91 94287 33427 | E-mail : thegoswami@gmail.com | canilesh.vgc@gmail.com | www.goswami.in

**Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements ) Regulations, 2015( as amended)**

**TO THE BOARD OF DIRECTORS OF MEDICO INTERCONTINENTAL LIMITED**

We have reviewed the accompanying Statements of Consolidated Unaudited Financial Results of MEDICO INTERCONTINENTAL LIMITED ("the Holding Company " ) and its subsidiaries (the Holding and its subsidiaries together referred to as "the Group" ) , for the quarter ended June 30, 2021 ("the Statement") , being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the SEBI from time to time.

This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity ', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Parent Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.





**V.GOSWAMI & CO.**  
**CHARTERED ACCOUNTANTS**

PEER REVIEW :- 011190  
ISO 9001:2015 CERTIFIED  
MSME :- GJ01D0134595  
GST : 24AAHFV3075F1Z7

3, SF, Manek Appartment, Nr. Jain Derasar, Above Dena Bank, Nehrunagar Circle, Ahmedabad-380015.  
M : +91 94287 33427 | E-mail : thegoswami@gmail.com | canilesh.vgc@gmail.com | www.goswami.in

The Statement included the results of following subsidiary company:-

- 1.EVAGRACE PHARMA PRIVATE LIMITED
- 2.RITZ FORMULATIONS PRIVATE LIMITED
- 3.SUNGRACE PHARMA PRIVATE LIMITED
- 4.AZILLIAN HEALTHCARE PRIVATE LIMITED

Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 7 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

We did not review the interim financial results of the subsidiaries included in the consolidated unaudited financial results, whose financial results reflect, total revenues of Rs. 1535.84 Lakhs , total net profit after tax of Rs. 40.53 Lakhs for the quarter ended June 30, 2021 as considered in the Statement whose financial results have not been reviewed by us. These interim financial results have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of the subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above. Our conclusion on the Statement is not modified in respect of these matters.

For, V. GOSWAMI & CO,  
Chartered Accountants  
(FRN:0128769W)

Nilesh Purohit  
(Partner)

Mem No:162541

Date :-Ahmedabad

Place :-14/08/2021

UDIN: 21162541AAAADA2451





**Statement of Consolidated Unaudited Financial Results for the Quarter ended June 30, 2021**

(Rs. in lakhs)

Sr. No.	Particulars	Quarter ended			Year ended
		CONSOLIDATED			CONSOLIDATED
		3 Months ended	Preceding 3 Months ended	Corresponding 3 months ended in previous year	Previous year ended
		30-06-2021	31-03-2021	30-06-2020	31-03-2021
		Unaudited	Refer note-3	Unaudited	Audited
	<b>Revenues</b>				
1	Revenue from Operations				
2	Other Income	2355.39	1453.38	1986.25	6974.05
3	<b>Total Revenue (A)</b>	1.07	0.24	13.03	17.84
4	<b>Expenses</b>	<b>2356.46</b>	<b>1453.62</b>	<b>1999.28</b>	<b>6991.89</b>
	(a) Cost of materials consumed				
	(b) Purchases of stock-in-trade	0.00	0.00	0.00	0.00
	(c) Changes in inventories of finished goods and stock-in-trade	1774.40	1149.08	1805.30	5805.24
	(d) Employee benefits expense	187.97	29.06	-129.10	-43.38
	(e) Finance costs	42.33	47.92	58.81	217.39
	(f) Depreciation and amortisation expense	28.71	30.49	33.38	127.99
	(g) Other expenses	4.30	3.86	2.92	13.74
	<b>Total Expenses (B)</b>	<b>219.48</b>	<b>107.99</b>	<b>139.21</b>	<b>517.70</b>
5	<b>Profit/(Loss) before exceptional items &amp; tax (1-4)</b>	<b>2257.19</b>	<b>1368.40</b>	<b>1910.52</b>	<b>6638.68</b>
6	Exceptional items	99.27	85.22	88.76	353.21
7	<b>Profit/(Loss) for the period from operations before tax (5+6)</b>	<b>99.27</b>	<b>85.22</b>	<b>88.76</b>	<b>353.21</b>
8	<b>Tax expense</b>	<b>99.27</b>	<b>85.22</b>	<b>88.76</b>	<b>353.21</b>
	(a) Current Tax	25.27	28.57	22.23	95.59
	(b) Deferred Tax	25.43	28.42	22.14	95.20
9	<b>Profit/(Loss) for the period from continuing operations (7-8)</b>	<b>74.00</b>	<b>56.65</b>	<b>66.53</b>	<b>257.62</b>
10	Profit/(loss) for the period from discontinued operations	0.00	0.00	0.00	0.00
11	Tax expense of discontinued operations	0.00	0.00	0.00	0.00
12	Profit/(loss) for the period from Discontinued operations (after tax)	0.00	0.00	0.00	0.00
13	<b>Profit/ (loss) for the period (After tax)</b>	<b>74.00</b>	<b>56.65</b>	<b>66.53</b>	<b>257.62</b>
14	Other Comprehensive Income	0.00	0.00	0.00	0.00
15	<b>Total Comprehensive Income for the period (13+14)</b>	<b>74.00</b>	<b>56.65</b>	<b>66.53</b>	<b>257.62</b>
	Paid-up Equity Share Capital (Face Value INR 10 each)	324.90	324.90	324.90	324.90
16	<b>Earnings Per Equity Share of Rs. 10 each (for continuing Operations)</b>				
	(a) (Basic) - INR	2.28	1.74	2.05	7.93
	(b) (Diluted) - INR	2.28	1.74	2.05	7.93
17	<b>Earnings Per Equity Share of Rs. 10 each (for discontinuing Operations)</b>				
	(a) (Basic) - INR	0.00	0.00	0.00	0.00
	(b) (Diluted) - INR	0.00	0.00	0.00	0.00
18	<b>Earnings Per Equity Share of Rs. 10 each (for continuing &amp; discontinuing Operations)</b>				
	(a) (Basic) - INR	2.28	1.74	2.05	7.93
	(b) (Diluted) - INR	2.28	1.74	2.05	7.93

- The above unaudited consolidated financial results of the Company for the quarter ended June 30, 2021 have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on August 14, 2021. The above results reviewed by statutory auditors and who have expressed an unmodified opinion on these results.
- During the quarter ended 30th June, 2021, the company is operating in single segment. So segment reporting is not applicable for this quarter, but segment information shall be provided when it applicable.
- Figures for the quarter ended 31st March, 2021 are the balancing figures between audited figures for the full financial year and the reviewed year to date figures up to the third quarter of the financial year.
- The Company has considered possible effects that may result from COVID-19 in preparation of these results including recoverability of assets including inventories and trade receivables. In developing the assumptions relating to future uncertainties in the economic conditions due to COVID-19, it has, at the date of approval of these results, used relevant internal and external sources of information including economic forecasts and expects that the carrying amounts of these assets are recoverable. The impact of COVID-19 may be different from that estimated as at the date of approval of these consolidated financial results.
- The previous period figures have been re-grouped / reclassified, wherever considered necessary, to make them comparable.

Place: Ahmedabad  
Date: 14/08/2021

For, Medico Intercontinental Limited

SAMIR SHAH  
MANAGING DIRECTOR  
DIN: 03350268

